• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effect of methotrexate, anti-TNFα and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A

tetano

Editor, Senior Moderator
Arthritis Care Res (Hoboken). 2013 Dec 10. doi: 10.1002/acr.22246. [Epub ahead of print]
Effect of methotrexate, anti-TNFα and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis.
Hua C, Barnetche T, Combe B, Morel J.
Author information
Abstract
OBJECTIVE:

To assess the current literature on the impact of rheumatoid arthritis (RA) treatments on the humoral response to pneumococcal and influenza vaccines.
METHODS:

We systematically searched the literature for studies evaluating the immune response to vaccines in RA patients receiving methotrexate (MTX) and/or biologics. The efficacy of vaccination, assessed by response rate based on increased antibody titers before and 3 to 6 weeks after vaccination, was extracted by one investigator and verified by another.
RESULTS:

12 studies were included. RA patients mainly received MTX, anti-TNFα or rituximab (RTX). Influenza vaccination response was reduced for RTX (43 patients. Pooled odds-ratio (OR), 0.44 [95% CI, 0.17-1.12] for strain H1N1, 0.11 [0.04-0.31] for H3N2, 0.29 [0.10-0.81] for B) but not anti-TNFα (308 patients. OR, 0.93 [0.36-2.37] for H1N1, 0.79 [0.34-1.83] for H3N2, 0.79 [0.37-1.70] for B). For MTX, results differ depending on the method of analysis (222 patients. OR, 0.35 [0.18-0.66] for at least 2 strains, ORs close to 1.0 in the single strain analysis). Pneumococcal vaccination response was reduced for 139 patients receiving MTX compared to controls (OR, 0.33 [0.20-0.54] for serotype 6B, 0.58 [0.36-0.94] for 23F) but not anti-TNFα (258 patients. OR, 0.96 [0.57-1.59] for 6B, 1.20 [0.57-2.54] for 23F). For RTX, response was reduced (88 patients. OR, 0.25 [0.11-0.58] for 6B and 0.21 [0.04-1.05] for 23F).
CONCLUSION:

MTX decreases humoral response to pneumococcal vaccine and may impair response to influenza vaccine. The immune response to both vaccines is reduced with RTX but not anti-TNFα therapy in RA patients. ? 2013 American College of Rheumatology.

Copyright ? 2013 American College of Rheumatology.

PMID:
24339395
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24339395
 
Back
Top Bottom